Feline injection-site sarcoma : ABCD guidelines on prevention and management by Hartmann, K. et al.
Introduction
Recently, vaccination of cats has received scientific and public attention
linked to the supposition that a range of rare adverse effects can arise
following vaccination. in cats, the most serious of these adverse conse-
quences is the occurrence of invasive sarcomas (mostly fibrosarcomas),
so-called ‘feline injection-site sarcomas’ (FiSSs), that can develop with-
in the skin at sites of previous vaccination. despite extensive research
on the pathogenesis of these sarcomas, there is no definitive causal 
relationship that explains their occurrence and the direct link to 
vaccination. The most accepted hypothesis suggests that a chronic
inflammatory reaction at the site of injection provides a trigger for 
subsequent malignant transformation. 
Epidemiology and characterisation
in 1991, an increased incidence of tumours in cats that developed at
injection sites was first reported in the United States.1 This observation
was connected to an increased use of rabies and feline leukaemia virus
(FeLV) vaccinations.2,3 As a consequence, these tumours were first
called feline ‘vaccine-associated sarcomas’. However, the subsequent
finding that other, non-vaccinal injectables can also cause this type of
tumour has led to reclassification of these neoplasms as ‘feline injec-
tion-site sarcomas’ (FiSSs). These tumours seem to be unique to cats,4
although comparable tumours have been reported in ferrets5 and very
occasionally in dogs.6
FiSSs occur at sites typically used for vaccination and injections, such
as the interscapular region (Figure 1), the lateral thoracic or abdominal
wall, the lumbar region, and the area of the semimembranosus and
semitendinosus muscles. FiSSs are most commonly located in the sub-
cutis, but also can occur intramuscularly.7,8
FiSSs can occur as early as 4 months and up to 3 years after an injec-
tion. They are characterised by invasive local growth in the subcutis,
often with spread along fascial planes.9 Most FiSSs are fibro sarcomas,10
but other malignancies, such as osteosarcomas,11 chondrosarcomas,7
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Overview: In cats, the most serious of adverse
effects following vaccination is the occurrence 
of invasive sarcomas (mostly fibrosarcomas): 
so-called ‘feline injection-site sarcomas’ (FISSs).
These develop at sites of previous vaccination or
injection. They have characteristics that are distinct
from those of fibrosarcomas in other areas and
behave more aggressively. The rate of metastasis
ranges from 10–28%.
Pathogenesis: The pathogenesis of these
sarcomas is not yet definitively explained. However,
chronic inflammatory reactions are considered the
trigger for subsequent malignant transformation.
Injections of long-acting drugs (such as
glucocorticoids, and others) have been associated
with sarcoma formation. Adjuvanted vaccines induce
intense local inflammation and seem therefore to 
be particularly linked to the development of FISS. 
The risk is lower for modified-live and recombinant
vaccines, but no vaccine is risk-free.
Treatment and prevention: Aggressive, radical
excision is required to avoid tumour recurrence. 
The prognosis improves if additional radiotherapy
and/or immunotherapy (such as recombinant feline
IL-2) are used. For prevention, administration of any
irritating substance should be avoided. Vaccination
should be performed as often as necessary, 
but as infrequently as possible. Non-adjuvanted,
modified-live or recombinant vaccines should 
be selected in preference to adjuvanted vaccines.
Injections should be given at sites at which 
surgery would likely lead to a complete cure; the
interscapular region should generally be avoided.
Post-vaccination monitoring should be performed.
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rhabdomyosarcomas,7 malignant fibrous
histio cytomas,7,11 and myofibroblastic sarco-
mas8 have also been described. 
FiSSs have histological characteristics that
are distinct from those of fibrosarcomas in
other areas. Typically there is perivascular
infiltration of lymphocytes and macrophages
at the tumour periphery, a central area of
necrosis, inflammation and local infiltration of
tumour cells (Figure 2).10,12 FiSSs behave more
aggressively than sarcomas at other sites.13
The rate of metastasis ranges from 10–28%.14,15
The lung is the most common site of metasta-
sis, followed by regional lymph nodes and
abdominal organs, such as the kidney, spleen,
intestine and liver.16,17
in the past 20 years, an epidemiological asso-
ciation has been demonstrated between vaccina-
tion and the later development of FiSS.3,13,18–21
The incidence of FiSS has been estimated at 1–4
in every 10,000 vaccinated cats in the USA,22,23
and the ratio of injection-site to non-injection-
site sarcomas increased from 0.5 in
1989 to 4.3 in 1994.10 in one study
in the USA, reported rates of reac-
tion were 0.3 FiSSs per 10,000 
vaccinations and 11.8 postvaccinal
inflammatory reactions per 10,000
vaccinations in cats.22 if inflamma-
tory reactions are a necessary prel-
ude to FiSS, then these rates
suggest that 1 in 35–40 inflamma-
tory reactions develop into FiSS. 
in the UK, the incidence of FiSSs
seems to be relatively low (inci-
dence risk of FiSS per year was
estimated to be 1 per 16,000–50,000
cats registered by practices, 1 per
10,000–20,000 cat consultations,
and 1 per 5000–12,500 vaccination
visits).24 one reason for the low
rate might be that rabies vaccina-
tion is not a routine procedure for
cats in the UK. one study in
Canada investigated the annual
prevalence of feline postvaccinal
sarcomas among 11,609 feline skin
mass submissions from 1992 to
2010 and revealed no decrease in
disease prevalence or increase in
age of affected cats in response to
change in vaccination formulation
or recommended changes in feline
vaccination protocols.25
Pathogenesis
despite extensive research, there
is no definitive proof of the
pathogenesis of FiSS. The most
widely accepted hypothesis sug-
gests that a chronic inflammatory
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reaction at the site of an injection acts as a trig-
ger for subsequent malignant transformation.
Adjuvanted vaccines seem to be particularly
linked to the development of FiSS due to the
more intense local inflammation associated
with such products. This idea is supported by
frequent identification of adjuvants in histo-
logical or ultrastructural investigations of
these sarcomas.12,18
Many data suggest an association between
vaccination and FiSS in cats. Aluminium, a vac-
cine adjuvant, has been found in biopsy sam-
ples of FiSS.26 in most inactivated vaccines, an
adjuvant is added to enhance the inflammation
at the site of injection, which is intended and
necessary when applying a killed agent in
order to trigger the necessary immune
response. However, this inflammation might
potentially lead to malignant transformation.
Traces of adjuvants can be seen in the inflam-
matory reaction, specifically accumulated
within macrophages or multi nucleate giant
cells, and later in histological 
sections of FiSS in the trans-
formed fibroblast.18 intracellular
crystalline particulate material
was found in an ultrastructural
study in 5 of 20 FiSSs investigat-
ed, and in one of the five cases
was identified as aluminium-
based.12 Although no specific 
vaccine or adjuvant has been
incriminated,27 local irritation
from adjuvant is thought to stim-
ulate mainly fibroblasts to the
point that malignant transforma-
tion occurs. 
At first, only rabies and FeLV
vaccines were identified as risk
factors,3,13,23 but subsequently
other vaccines, including vac-
cines against feline panleuko -
penia virus (FPV), feline
herpesvirus-1 (FHV-1) and feline
calicivirus (FCV), were also
found to be involved in the
development of FiSS in some
cases.13,23,28–30 in addition to vac-
cines, injections  such as long-act-
ing glucocorticoids, penicillin,
lufen uron,27,31,32 cisplatin33 and
meloxicam34 have been associat-
ed with sarcoma formation. one
study found that the frequency
of administration of long-acting
glucocorticoid injections (dexa -
methasone, methyl prednisolone
and triam cinolone) was signifi-
cantly higher in cats with FiSS in
the interscapular region than in
control cats.35 Fibrosarcomas
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angiogenesis. overexpression of growth fac-
tors and oncogene activation have been
demonstrated in cats with FiSS and are sus-
pected to play a role in tumour develop-
ment.40–42
As vaccination against FeLV is associated
with a higher risk of FiSS, some studies
looked at a possible role of FeLV and its
mutant feline sarcoma virus (FeSV) in the
development of FiSS, but could not detect
either FeLV or FeSV in the tumours.43
Furthermore, no other viruses, including
feline immunodeficiency virus, feline foamy
virus, polyomaviruses or papillomaviruses
were detected in tumour tissues.44–47 No evi-
dence has been found to implicate replication
or expression of endogenous retroviruses in
FiSS formation.45,46
The observation that not all cats develop
FiSS after vaccination suggests that there
might be a genetic predisposition. it has been
suggested that there is a higher incidence of
FiSS in siblings of affected cats, and that some
cats tend to develop more than one FiSS.
Alterations with unknown relevance such as
hyperploidy,48 translocations49 and triploidy50
of oncogene and tumour suppressor loci 
have been found on extra chromosomes and
monosomic chromosomes in affected cats.
Mutations have been identified in the 
tumour suppressor gene p53, which is 
implicated in cancer initiation and progres-
sion in sarcoma tissue of cats with FiSS.51–55
A case-control study (50 domestic shorthair
cats with a confirmed diagnosis of FiSS and
100 disease-free matched controls) investigat-
ing a possible association between polymor-
phisms in the genomic sequence of the feline
p53 gene and a predisposition to FiSS, found a
strong association between FiSS and the 
presence of specific nucleotides at two of the
polymorphic sites.56 However, another study,
conducted in Munich, Germany, could not
reproduce these findings and observed no
association with the polymorphisms
described.57
a deep, non-absorbable suture in one cat;36
around a surgical swab in the abdomen of one
cat;37 adjacent to the site of microchip implan-
tation in two cats;38,39 and associated with a
subcutaneous fluid port device.38,39 This 
suggests that all inflammatory reactions, 
theoretically, have the potential to lead to the
development of FiSS by triggering uncon-
trolled proliferation of fibroblasts and myo -
fibroblasts, which, in some cases, results in
malignant transformation. 
Although many causes of inflammation are
associated with FiSS development, the risk
seems to be higher for vaccines compared
with other injections; among vaccines, the risk
seems to be higher when adjuvanted vaccines
are used. Srivastav et al35 compared associa-
tions between vaccine types and other
injectable drugs with the development of FiSS
in a case-control study of 181 cats with soft tis-
sue sarcomas (cases), 96 cats with tumours at
non-vaccine regions (control group 1), and 159
cats with basal cell tumours (control group 2).
There was a significant association between
the administration of various types of vac-
cines and other injectable products (eg, long-
acting corticosteroids) and FiSS development.
of 192 cats with sarcoma, 101 had vaccina-
tions at the site of tumour development dur-
ing the preceding 3 years, and 23 had received
other injections.35 This study also showed that
adjuvanted inactivated vaccines were signifi-
cantly more commonly associated with FiSS
development than other vaccines; of 35 vacci-
nated cats with sarcoma on the hindlimb, 25
cats had received adjuvanted vaccines, seven
cats had received modified-live virus (MLV)
vaccines (FPV, FHV-1 and FCV), and only one
cat had received a recombinant vaccine. These
findings also indicated that no vaccines are
risk-free.35
The mechanism by which the inflammatory
reaction causes tumour formation is not fully
understood. Growth factors promote prolifer-
ation, can induce malignant transformation,
and also can be involved in the regulation of
Figure 2 Histological sections 
of a 2 cm diameter mass removed
from the lateral thorax of a 
13-year-old domestic shorthair
cat. A similar interscapular mass
had been removed from this cat 
2 months previously. (a) A focus
of lymphoplasmacytic
inflammation is contained 
within the surrounding sarcoma. 
(b) Higher magnification of 
the neoplastic tissue reveals 
a pleomorphic population of
neoplastic spindle cells with
occasional  giant nuclei and
irregular mitotic activity (arrow).
Haematoxylin and eosin stain.
Courtesy of Michael Day, School 





Board on Cat Diseases
(ABCD) is a body of experts
in immunology, vaccinology
and clinical feline medicine 
that issues guidelines on
prevention and management
of feline infectious diseases in
Europe, for the benefit of the
health and welfare of cats.
The guidelines are based on
current scientific knowledge
of the diseases and available
vaccines concerned.
The latest version of the
guidance provided in this
article is available at
www.abcdcatsvets.org 
and www.abcd-vets.org
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Management
Appropriate treatment should first include
staging and careful planning of the surgery,
because aggressive, radical excision is crucial 
to avoid tumour recurrence. The prognosis
improves if, in addition to radical surgery,
adjunctive treatments such as radiotherapy or
immunotherapy are used. Preoperatively, (con-
trast-enhanced) computed tomography (CT) or
magnetic resonance imaging (MRi) should be
obtained for staging, and to determine the
extent of the tumour and the size of the radia-
tion field required to maximise the chance of a
successful outcome.58 it was shown that the
actual size of tumours determined by CT could
be twice that estimated at physical examina-
tion.59,60 Surgeons should attempt to achieve
complete, en bloc, surgical tumour resection
with at least 3 cm (ideally, 5 cm) margins61
[EBM grade iii] and the removal of one fascial
plane underlying the tumour, because incom-
plete resection can result in recurrence as early
as 2 weeks after surgery [EBM grade iii].28,62
Treatment using surgical excision alone has a
recurrence rate of up to 70%, with tumour
regrowth usually occurring in the first 
6 months after surgery [EBM grade iii].13
Tumour-free margins are very important for a
longer disease-free interval, which was 700
days when complete tumour excision was
accomplished, but only 112 days for incomplete
resection [EBM grade iii].63 However, even
with clean surgical margins, the recurrence rate
can be as high as 50% [EBM grade iii].64
Preoperative or postoperative radiation
therapy significantly decreases recurrence
rates and prolongs remission times,16,63,65
while the benefit of chemotherapy is not
proven as large prospective randomised con-
trolled trials are lacking. one non-randomised
study found no significant difference between
control cats (surgery alone) and cats treated
with surgery and doxorubicin [EBM grade
iii],66 while a recent study demonstrated
chemotherapy benefits compared with histor-
ical controls using a combination of neoadju-
vant and adjuvant chemotherapy (three
epirubicin doses before and after surgery)
[EBM grade iii].67 Chemotherapy mainly
remains an option for palliative treatment in
cats with non-resectable FiSS, when radiation
therapy is not available. 
Additional immunotherapy appears to be
promising.68–70 Results of prospective ran-
domised controlled studies of cytokine gene
transfer techniques for adjuvant-immunologi-
cal treatment of FiSS showed reduced recur-
rence rates. in cats receiving gene therapy by
the peritumoural administration of histo-
incompatible Vero cells expressing human
interleukin-2 (hiL-2) in addition to surgery and
radiation therapy, only 5/16 (31%) had FiSS
recurrence, while 11/16 control cats (69%) that
had surgery and radiation therapy, but no
immunotherapy, had FiSS recurrence within 16
months [EBM grade i].71 Use of neoadjuvant
gene therapy using a non-viral vector that
expresses feline granulocyte-macrophage
colony-stimulating factor (GM-CSF) or a com-
bination of the feline genes GM-CSF, inter-
leukin (iL)-2 and interferon-γ (iFN-γ) was well
tolerated by cats [EBM grade i]68,69 and showed
promising results. Recombinant feline iL-2 is
now commercially available in Europe for 
the treatment of FiSS in combination with 
surgical excision and radiation therapy. in a
randomised controlled clinical trial, adminis-
tration of a recombinant canarypox virus
expressing feline iL-2 was well tolerated and
resulted in a significantly longer median time
to relapse and a significant reduction in the risk
of relapse at 1 year and 2 years [EBM grade i].70
Prevention
Prevention consists of three general consider-
ations: 
Choice of injection site
in general, injecting distally in a leg aids,
where necessary, in the subsequent treatment
of sarcoma by amputation of the leg (because
these tumours are very difficult to excise 
completely and often recur after resection).20
Administration of vaccines (or other injec-
tions) between the scapulae is generally 
contraindicated because tumour resection is
almost impossible in this location. 
To assess the acceptance of the recommen-
dations of the Vaccine-Associated Feline
Sarcoma Task Force (VAFSTF), published in
1996, a study involving 392 cats with FiSSs
compared the anatomical locations of
tumours between cases with FiSS diagnosed
before and after publication of these recom-
mendations.72 The proportions of FiSS signifi-
cantly decreased in the interscapular (53% to
40%) and right and left thoracic (10% to 4%
and 9% to 1%, respectively) regions, whereas
EBM grades
The ranking system






of this article is
described on 
page 574 of this
Special Issue.
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Key considerations in the prevention of FISS
< Injections in cats should always be given at sites at which surgery (such
as amputation of a limb or excision of lateral abdominal skin) would likely
lead to a complete cure with the least complicated surgical procedure
< General recommendations to reduce the inflammatory reaction at
injection sites should be followed, such as avoiding the administration 
of irritating substances
< It is advised to vaccinate only as often as necessary and as infrequently
as possible (eg, according to the principles of current vaccination
guidelines, avoiding FeLV vaccination in FeLV antigen-positive, 
FeLV PCR-positive or FeLV antibody-positive cats)
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the proportions of FiSS significantly increased
in the right thoracic limb (1% to 10%) and the
combined regions of the right pelvic limb with
the right lateral aspect of the abdomen (13% to
25%) and the left pelvic limb with the left 
lateral aspect of the abdomen (11% to 14%).
Thus, while veterinarians are complying with
vaccination recommendations to some extent, 
a high proportion of tumours still developed 
in the interscapular region. There was also an
increase in lateral abdominal FiSSs, which
could be attributable to aberrant placement of
injections intended for the pelvic limbs. it
remains the case that only administration of
vaccines as distally as possible on a limb allows
for complete surgical margins if limb amputa-
tion is required [EBM grade iii].73 Current data
in Europe shows a similar situation. in a study
examining the location of FiSSs in cats present-
ed to the oncology service at the University
teaching hospital in Munich, most still occurred
between the scapulae (40%), followed by the
right (19%) and left thoracic walls (13%).74
Unfortunately, there is still insufficient clini-
cal information to enable evidence-based 
vaccine site recommendations. The majority of
safety and efficacy data comes from licensing
studies in which vaccines are administered
subcutaneously in the interscapular region
(which should not be used for any injection in
the clinical setting). Current research indicates
that radical surgical resection of injection-site
sarcomas including margins of at least 3 cm,
but preferably 5 cm [EBM grade iii],61 is associ-
ated with the highest response rate and long-
term survival [EBM grade iii].15 With this in
mind, the Feline Vaccination Advisory Panel of
the American Association of Feline Practi -
tioners (AAFP) conducted an informal survey
of veterinarians whose practices focused on
radiation (12), surgical (36), and medical (44)
oncology for opinions on what the preferred
vaccination sites should be.62 These experts
agreed that distal to the stifle, followed by 
distal to the elbow, were their preferred sites.
Nearly as popular was the tail. Res pondents
frequently commented that vaccines should 
be administered as low on the leg as possible.
They added that vaccination of cats resting in a
crouched position often resulted in inadvertent
injection of the skin fold of the flank, leading to
tumours that were difficult to resect.62 This is
reflected in a recent paper that found an
increase in lateral abdominal injection-site sar-
comas since the publication of the VAFSTF’s
vaccination recommendations in 1996.61
Based on these expert opinions, the AAFP
now recommends in its new guidelines,62 con-
sistent with the earlier (2006) guidelines,75 that
vaccines against FPV, FHV-1 and FCV should
be administered below the right elbow; FeLV
vaccines should be administered below the
left stifle; and rabies vaccines should be
administered below the right stifle.62 So far,
vaccination in the tail has not been considered
a practical option. However, a recent pilot
study demonstrated that vaccination in the
tail was well tolerated and that tail-vaccinated
cats developed an antibody response compa-
rable to that observed following injection of
the vaccine distally in the leg [EBM grade ii].76
Further studies are warranted to confirm
whether this would be an alternative option
leading to equal protection rates.
Alternative recommendations are made by
the Vaccination Guidelines Group (VGG) of
the World Small Animal Veterinary Asso -
ciation, which recognises the practical difficul-
ties often faced by veterinarians attempting
vaccination into limbs or the tail. The advice
of the VGG is that a preferred site for vaccine
delivery (and surgical resection of a FiSS that
might arise) is the skin over the lateral
abdomen. This is a procedure that appears
well tolerated in the majority of cats. 
As a general recommendation, recording the
sites of injections in the patient’s medical records
is important. in addition, post-vaccination 
monitoring plays a vital role (see box).
Recommendations for reducing
inflammatory reactions
in terms of preventing inflammatory reactions
at injection sites, there are a few recommenda-
tions to follow. Cats should receive as few 
subcutaneous injections as possible. intra -
muscular injections in cats should be avoided
because intramuscular tumours develop with
a similar frequency, but are more difficult to
detect early. Whenever feasible, cats should
receive drugs orally or intravenously. The 
subcutaneous injection of long-acting irritating
substances (such as long-acting glucocorti-
coids) should be avoided.
one study examined potential risk factors
when administering vaccines27 and few factors
Veterinarians should instruct their
clients to monitor vaccination (and
other injection) sites for swelling or
lumps in order to
detect potential sarco-
mas early and at a time





Incisional wedge biopsies or total
removal and histological examination
of any mass is warranted if the mass
is still present 3 months after vacci-
nation, if the mass becomes larger
than 2 cm in diameter, or is increas-
ing in size 1 month
after vaccination.
In general, a diag-
nostic work-up is war-
ranted when any
cutaneous mass is
noted in a cat. FISSs
are usually firm, indo-
lent, seemingly well-circumscribed,
subcutaneous masses that are often
not freely moveable.
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< Vaccination of cats provides essential protection and should not be stopped 
because of the risk of feline injection-site sarcoma (FISS).
< Vaccines are not the only injectable medical products associated with FISS.
< An individual vaccination schedule is important. Cats should be vaccinated no 
more than necessary, in accordance with current guidelines.
< Appropriate sites for injection should be selected. The interscapular region should
generally be avoided. Vaccines should be injected at a site from which a mass can easily 
be surgically removed, such as distally on a leg or in the skin of the lateral abdomen.
< Vaccines should be brought to room temperature prior to administration, but should 
not be kept unrefrigerated for hours.
< Whenever possible, subcutaneous, rather than intramuscular, injection should be performed.
< The preference is for: non-adjuvanted vaccines over those containing adjuvant; modified-
live vaccines or recombinant vaccines over inactivated vaccines; and vaccines with a long
duration of immunity.
< Post-vaccination monitoring should be performed. Any lump at the site of injection that 
is still present 3 months after vaccination, that is larger than 2 cm in diameter, or that it is
increasing in size 1 month after vaccination should be surgically removed.
KEY points
were associated with the development of FiSS.
it was observed that the size of the needle and
the syringe, the velocity of injection, and
whether manual pressure was applied after
injection or not, played no role. in contrast, the
temperature of the vaccine made a significant
difference, with cold vaccines being associated
with a higher risk of FiSS development than
vaccines at room temperature.27 Thus, vaccines
should be taken out of the refrigerator about
15 minutes before injection, but not much
longer, to avoid reduction in vaccinal efficacy.
if available, intranasal or oral vaccines would
be preferable over injectable vaccines in cats.
However, in most countries only injectable vac-
cines are available. Therefore, vaccines are 
preferred that cause the least subcutaneous
inflammatory reaction. Vaccines without adju-
vants should be used rather than adjuvant-
containing vaccines, which means that MLV or
recombinant vaccines (eg, canarypox-vectored
vaccine) without adjuvant are preferred over
inactivated vaccines with adjuvants.
it has been shown that recombinant canary-
pox-vectored vaccines cause less inflamma-
tion at the injection site. This was
demonstrated in rats,77 and in a study in cats,
in which the typical granulomatous inflam-
mation did not develop at the injection site
when using these particular vaccines.78 An
extensive study investigating the subcuta-
neous tissue response following administra-
tion of a single dose of multi-component
vaccines confirmed these findings.79 Three
groups of 15 cats were injected with one of
three vaccines or saline as a negative control;
cats in group A received a non-adjuvanted
recombinant canarypox-vectored FeLV vac-
cine; cats in group B received an FeLV vaccine
with a lipid-based adjuvant; and cats in group
C were vaccinated with an FeLV vaccine adju-
vanted with an alum-Quil A mixture. on days
7, 21 and 62 post-vaccination, significantly
less inflammation was associated with admin-
istration of the non-adjuvanted recombinant
canarypox-vectored vaccine. The inflamma-
tion was most severe in the cats receiving the
aluminium-based adjuvant. Cats receiving
adjuvanted vaccines had evidence of residual
adjuvant material accumulated within
macrophages even at 62 days post-vaccina-
tion.79 in a case-control study investigating
associations between vaccine types and devel-
opment of FiSS, adjuvanted inactivated vac-
cines were significantly more commonly
associated with sarcoma development than
other vaccines; of 35 vaccinated cats with sar-
coma on the hindlimb, 25 cats had received
adjuvanted vaccines, seven cats had received
MLV vaccines (FPV, FHV-1 and FCV), while
only one cat had received a recombinant
canarypox-vectored vaccine [EBM grade iii].35
Vaccination schedules
Finally, to prevent development of FiSS, cats
should be vaccinated no more than necessary.
Therefore, long vaccination intervals should
be applied in adult animals; vaccines (such as
rabies vaccines and FPV vaccines) that are
licensed for 3 year or even 4 year boosters
should be preferred; no FeLV or rabies vacci-
nations should be administered to indoor-
only cats; and immune cats should not be
vaccinated (eg, if antibodies are detected).
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